Postpartum Depression Therapeutics Market Worth US$ 55.14 Billion by 2031 - Growth Plus Reports
Growth Plus Reports
Updated 6 min read
Growth Plus Reports
Newark, New Castle, USA, June 20, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the global postpartum depression therapeutics market was valued at US$ 5.2 billion and is expected to rise at a revenue CAGR of 33% to reach US$ 55.14 billion by 2031.
The global market for postpartum depression therapeutics was analyzed, and it is expected to rise significantly during the forecast period. Postpartum depression is a condition that occurs in certain women following childbirth. It's a mental illness that causes depression, worries, and despair, making it difficult for a new mother to care for herself and her child.
Recent Development in the Global Postpartum Depression Therapeutics Market:
In February 2023, The FDA accepted the submission of a New Drug Application (NDA) for zuranolone treating major depressive disorder (MDD) and postpartum depression by Biogen Inc. and Sage Therapeutics, Inc. (PPD).
In January 2023, Woebot Health announced the enrollment of the very first patient in a pivotal clinical trial to observe the safety and efficacy of WB001, an investigational digital therapy for postpartum depression, granted Breakthrough Device Designation by the US Food and Drug Administration for 2021.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Key Takeaways:
Increasing awareness about postpartum depression among females is driving the market revenue share.
The antidepressant medicine segment, with its largest revenue share, dominates the global market.
Several advancements and increasing drug R&D are creating a strong product pipeline.
Market Drivers and Restraints:
The driving factor for the postpartum depression therapeutics market revenue is the rising prevalence of postpartum depression and the rising demand for effective therapies. Furthermore, the availability of many effective postpartum depression therapies, such as antidepressant drugs, is contributing to market revenue growth.
However, a lack of awareness among the population about postpartum depression is limiting market revenue growth.
Market Segmentation:
Segmentation By Type
Based on types, the global postpartum depression therapeutics market is segmented into postpartum anxiety, postpartum blues, postpartum post-traumatic stress disorder, postpartum psychosis, and others. The anxiety segment, with its significant revenue share, dominates the global market due to being the most common type of postpartum depression.
Segmentation By Drug Type
Based on the drug type, the global postpartum depression therapeutics market is segmented into antidepressants, antipsychotics, and others. Due to its effectiveness and wide utilization, the antidepressants segment accounts for the largest revenue share. Antidepressants boost the availability of neurotransmitters in the brain that are thought to be low in patients with depression, such as serotonin and norepinephrine.
Regional Growth Dynamics
Based on the region, the global postpartum depression therapeutics market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. Due to the availability of a sophisticated healthcare system, and an increase in the prevalence of postpartum depression, North America accounts for the most significant revenue share in the global market.
Following is a list of the top market players operating in the global market for postpartum depression therapeutics:
Novartis AG
Bausch Health Companies Inc.
GlaxoSmithKline plc
Sage Therapeutics, Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Report Coverage
Growth Plus Reports studied the global market for postpartum depression therapeutics in-depth and analyzed the basic market characteristics, significant investment areas, analytics of regional growth, revenue forecast, competitive market players, mergers, and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
Reimbursement Scenario
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL POSTPARTUM DEPRESSION THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY TYPE
Postpartum Anxiety
Postpartum Post-Traumatic Stress Disorder
Postpartum Blues
Postpartum Psychosis
Others
GLOBAL POSTPARTUM DEPRESSION THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE
Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031
Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
